European CHMP recommends approval of cenobamate (Ontozry) for treatment of adults with epilepsy

Cenobamate in intended to be licensed for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic therapies.

Source:

European Medicines Agency